This chapter provides information on some of the "en vogue" biomarker platforms and deals with cross-platform validation and transferring biomarkers between platforms. In addition, multiplex approaches are mentioned and their importance in the field of biomarker discovery and validation. The chapter elaborates on the currently low success rate in commercialization of biomarkers. It also presents examples of some successful commercialized biomarkers. The chapter focuses on five different technologies that have been widely used in biomarker identification and analysis: mass spectrometry (MS), enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance imaging (SPRi), reverse phase protein microarrays (RPMAs), and next-generation sequencing (NGS). It gives some examples of successful commercialization of biomarker assays. The outlook for biomarker research, discovery, and validation is favorable. Despite the issues raised in the chapter regarding biomarker discovery, the inherent issues with platform comparison and the inconsistencies in validation, biomarker discovery will remain a preferable research area.
